OBJECTIVE: To study the changes of hemostatic molecular markers in @entity3052 ( @entity3052 ) for elucidating their clinical significance. METHODS: A series of hemostatic molecular markers, including TF, @entity11524 , TAT, PAP, @entity2290 and @entity10431 were measured in 82 @entity3052 . RESULTS: The plasma levels of TF, TAT, @entity2290 and @entity10431 were elevated significantly at diagnosis in all @entity3052 @entity1 tested, while @entity11524 , @entity2786 did only in AML. After treatment, TF and TAT remained high in AML, @entity2290 and @entity10431 were still high in un-remission @entity1 . PAP and @entity2290 remarkably elevated in @entity1 with severe @entity548 . CONCLUSIONS: There existed @entity4461 as well as hyperfibrinolysis, which varied with @entity1778 types and was ameliorated with clinical improvement. The measurement of TF, TAT and PAP may provide useful information for the diagnosis of DIC. @entity2290 and @entity10431 may be considered as a useful indicator for prognosis. @entity1 with severe @entity548 should be treated with antifibrinolysis drugs. The prevention of @entity49 after treatment should be kept in mind.

[Clinical significance of hemostatic molecular markers in XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity10431 :: ('5329', 'Gene') :: ['u-PAR'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity49 :: ('MESH:D019851', 'Disease') :: ['hypercoagulability'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['AL', 'acute leukemia'] @entity11524 :: ('7035', 'Gene') :: ['TFPI'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity4461 :: ('MESH:D020141', 'Disease') :: ['hemostatic abnormality'] @entity2786 :: ('CHEBI:17985', 'Chemical') :: ['PAP'] @entity2290 :: ('5328', 'Gene') :: ['u-PA']
@entity3052 :: (MESH:D015470,Disease) :: ['acute leukemia']
